Decitabine combined with CAG for the treatment of atypical chronic myeloid leukemia: a case report and literature review

Atypical chronic myeloid leukemia BCR/ABL1 negative (aCML) is a rare hematopoietic stem/progenitor cell disorder characterized by neutrophilia, high rate of transformation to acute myeloid leukemia and poor survival. Currently, there is no consensus on the treatment for aCML. In this study, we repor...

Full description

Saved in:
Bibliographic Details
Published inTranslational cancer research Vol. 9; no. 8; pp. 5015 - 5019
Main Authors Cheng, Juan, Zhang, Hao, Ma, Hai-Zhen
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.08.2020
Subjects
Case Report
treatment
Decitabine
atypical chronic myeloid leukemia (aCML)
case report
CAG chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Atypical chronic myeloid leukemia BCR/ABL1 negative (aCML) is a rare hematopoietic stem/progenitor cell disorder characterized by neutrophilia, high rate of transformation to acute myeloid leukemia and poor survival. Currently, there is no consensus on the treatment for aCML. In this study, we report the case of a 52-year-old female aCML patient treated with decitabine in combination with CAG chemotherapy who achieved complete remission after the first course. The patient was subsequently treated with three cycles of the same regimen as consolidation treatment. Approximately two months after the completion of the fourth cycle, the patient was in good general health with less than 0.01% minimal residual leukemic cells. The findings of this case report indicate that decitabine in combination with CAG chemotherapy may be an effective treatment for aCML.
Bibliography:These authors contributed equally to this work.
ISSN:2218-676X
2219-6803
DOI:10.21037/tcr-19-1806